The 3D InSight™ Steatosis Model is an advanced human disease model that enables you to screen compounds and investigate disease pathophysiology using a physiologically relevant human liver organoid that recapitulates the first stage of non-alcoholic fatty liver disease: accumulation of lipids in liver hepatocytes.
Available as an assay-ready model delivered to your lab, or for use in 3D InSight™ Discovery Services, this diet-induced steatosis model includes a microtissue produced from a co-culture of healthy primary human hepatocytes, Kupffer cells, and liver endothelial cells, combined with specially formulated media and preparation of free fatty acids bound to bovine serum albumin for lipid-loading.
- Maintain susceptibility to induction of steatosis for up to 21 days in culture
- Assess multi-parametric steatotic endpoints, such as intra-cellular lipid content, reactive oxygen species production, mitochondrial impairment, and apoptosis, as well as changes at the mRNA and protein levels
- Evaluate efficacy and potency of steatosis drugs using InSphero-tested technical protocols with a 14-day assay window.
- Receive assay-ready disease models, ready to induce steatosis upon arrival at your lab after an incubation period of only a few hours.
Steatosis Induction in Liver Disease Microtissues
3D InSight™ Human Liver Disease Discovery Platform models use conjugated, quality-controlled, free fatty acids (FFA) bound to bovine serum albumin (BSA) for the efficient creation of a steatosis model to recapitulate the fatty liver disease state.
The bioavailable, conjugated FFA substrates are readily taken up, metabolized, and stored in primary human hepatocytes in our human liver organoid models, enabling the study of non-alcoholic fatty liver disease (NAFLD) and other dietary-induced liver diseases.